Home Press Release Imaging Biomarkers Market Size Projected to Reach $40.13 billion by 2034 | 12.32%

Imaging Biomarkers Market Size Projected to Reach $40.13 billion by 2034 | 12.32%

23 Jul, 2026

According to Straits Research, the global imaging biomarkers market size was valued at $14.15 billion in 2025 and is projected to reach $40.13 billion by 2034, growing at a CAGR of 12.32% during the forecast period 2026–2034.

Market Dynamics

The imaging biomarkers market is driven by the growing incorporation of advanced imaging analytics and artificial intelligence into clinical and research workflows, enabling the extraction of quantifiable biological information from medical images for earlier disease detection and personalized treatment planning. However, the market faces restraints due to the high cost of imaging equipment, radiopharmaceuticals, and data standardization, which limits accessibility across low-resource healthcare settings and complicate multi-center study harmonization. Despite these challenges, the market presents a strong opportunity through the expanding application of imaging biomarkers in precision medicine and drug development, where their ability to provide non-invasive, real-time assessment of therapeutic response is increasingly being leveraged to streamline clinical trials and accelerate regulatory approvals for novel targeted therapies.

Market Segments

  1. By Type (2026-2034)
    1. Anatomical biomarkers
    2. Functional biomarkers
    3. Molecular/Nuclear Biomarkers
    4. Quantitative Imaging Biomarkers
    5. Others
  2. By Technology (2026-2034)
    1. Positron Emission Tomography (PET)
    2. Ultrasound, Magnetic Resonance Imaging
    3. Computed Tomography (CT)
    4. Single-Photon Emission Computerized Tomography (SPECT)
    5. Others
  3. By Application (2026-2034)
    1. Diagnostics
    2. Drug Discovery & Development
    3. Personalized Medicine
    4. Disease Risk Assessment
    5. Others
  4. By End User (2026-2034)
    1. Hospitals
    2. Diagnostic/imaging centers
    3. Pharmaceutical and Biotech Companies
    4. Others